Overview
This investor presentation provides a comprehensive overview of Novo Nordisk's performance and strategic direction for the first six months of 2025. It details financial results, strategic aspirations across key therapy areas, pipeline updates, and market outlook.
Financial Highlights
- Sales growth of 18% (CER) driven by strong performance in Diabetes and Obesity care.
- Operating profit growth of 29% (CER).
- Positive free cash flow generation.
- Updated financial outlook for 2025 reflecting strong performance and market dynamics.
Strategic Aspirations 2025
- Purpose and Sustainability (ESG): Progress towards zero environmental impact, adding value to society, and being recognized as a sustainable employer.
- Innovation and Therapeutic Focus: Strengthening leadership in Diabetes, developing superior Obesity treatments, advancing Rare Disease pipeline, and establishing presence in Cardiovascular & Emerging Therapy areas.
- Commercial Execution: Aiming for significant market share in Diabetes, substantial sales growth in Obesity care, and sustained growth in Rare disease.
Pipeline and Market Updates
- Diabetes Care: Continued leadership with GLP-1 portfolio (Ozempic®, Rybelsus®), advancements in insulin (Insulin Icodec, IcoSema), and focus on cardiometabolic and renal outcomes.
- Obesity Care: Strong growth driven by Wegovy® and Saxenda®, with pipeline advancements including CagriSema, oral semaglutide, and amycretin, targeting significant unmet needs and comorbidities.
- Rare Disease: Focus on Haemophilia (Alhemo®, Mim8) and Growth Disorders (Norditropin®, Sogroya®), with a strategic expansion into new rare disease areas.
- Cardiovascular & Emerging Therapies: Expanding into areas like Cardiovascular Disease (Ziltivekimab), MASH (Semaglutide), and Alzheimer's Disease, leveraging existing capabilities and partnerships.
Manufacturing and Sustainability
Novo Nordisk is investing significantly in manufacturing capacity to meet growing demand and is committed to its purpose of defeating diabetes and other serious chronic diseases. Sustainability initiatives focus on zero environmental impact and social responsibility.
